Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check3 days agoChange DetectedThe footer now shows site revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now shows a 403 Forbidden error page instead of the study record content. The new page presents a minimal error screen with a Home link.SummaryDifference15%

- Check24 days agoChange DetectedRevision indicator on the page was updated from v3.6.6 to v3.7.0, signaling a platform update. This change affects only the version label and does not alter study information or user-facing features.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6, indicating a minor backend/content-management update to the study page.SummaryDifference0.0%

- Check59 days agoChange DetectedThe revision label was updated from v3.6.4 to v3.6.5 to reflect a newer page version. It represents an internal metadata update and does not change the study information presented.SummaryDifference0.0%

- Check80 days agoChange DetectedThe study page now shows revision v3.6.4, replacing the previous v3.6.3, indicating an updated version of the page content.SummaryDifference0.0%

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.